Advate

Advate (Octocog Alfa) is a recombinant coagulation factor VIII developed using advanced biotechnology to support individuals with hemophilia A, a genetic condition caused by a deficiency of factor VIII. It is produced without the use of human plasma or albumin, reducing the risk of transmission of blood borne pathogens and ensuring a high standard of safety and purity. Advate is designed to replace the missing clotting factor, helping the blood to clot more effectively and supporting normal hemostatic function.
This product is widely used for routine prophylaxis to reduce the frequency of bleeding episodes, as well as for on demand control of bleeding. It can also be used before surgical or dental procedures to maintain adequate factor VIII levels and support proper clot formation. Advate (250IU, 500IU, 1000IU, 1500IU dosage) is suitable for both adults and children and has been extensively studied across different age groups, demonstrating consistent performance and reliability.
Advate works by mimicking the activity of natural human factor VIII, binding with von Willebrand factor and participating in the intrinsic pathway of blood coagulation. By restoring factor VIII activity, it helps prevent spontaneous bleeding and supports faster recovery from bleeding events involving joints, muscles, or internal tissues.
Manufactured under strict quality controlled conditions, Advate undergoes multiple purification and viral inactivation steps to ensure product integrity. Its recombinant origin, clinical reliability, and well established safety profile have made Advate a trusted option in hemophilia care worldwide. Regular use, as guided by a healthcare professional, can help individuals maintain an active lifestyle and improve overall quality of life while managing hemophilia A effectively.